Literature DB >> 34433211

Serum 25(OH)D Concentration and Cardiovascular Disease Risk Markers Among Middle-Aged Healthy and Type 2 Diabetic Subjects.

Yogita Dhas1, Joyita Banerjee1, Gauri Damle2, Neetu Mishra1.   

Abstract

Vitamin D deficiency is a major widespread health concern and is linked to a high risk of cardiovascular disease (CVD). Thus, we have investigated the association of vitamin D with various CVD risk markers. The present study comprises 90 control and 90 type 2 diabetes mellitus (T2DM) subjects of both sexes (age range, 30-50 years). The 25 hydroxyvitamin D [25(OH)D] and CVD risk markers including high sensitive C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), intact parathyroid hormone (I-PTH), fibroblast growth factor (FGF)-23, erythrocyte sedimentation rate (ESR), and fibrinogen were measured by using standard assays. Blood viscosity and atherogenic index of plasma calculated using standard formulae. The ten-year cardiovascular risk was assessed using the Framingham risk score (FRS). 25(OH)D, hs-CRP, MCP-1, FGF-23, ESR, fibrinogen, atherogenic index of plasma and FRS were significantly different between control and T2DM groups (p<0.05). 25(OH)D showed a significant negative correlation with MCP-1, ESR, blood viscosity, atherogenic index of plasma and FRS among total study subjects. Further, logistics regression analysis showed an association of 25(OH)D with MCP-1, hematocrit, fibrinogen, and blood viscosity. The association between 25(OH)D and various CVD risk markers suggests that 25(OH)D might help in the prediction of CVD risk. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34433211     DOI: 10.1055/a-1534-2747

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  1 in total

1.  Associations between serum vitamin D3, atherogenic indices of plasma and cardiometabolic biomarkers among patients with diabetes in the KERCADR study.

Authors:  Mohammad Reza Mahmoodi; Hamid Najafipour
Journal:  BMC Endocr Disord       Date:  2022-05-12       Impact factor: 3.263

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.